tirzepatide osa trial for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight Lilly's weight-loss drug reduces sleep

Glucagon and GLP- 1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial

While GLP-1 is most known for its weight loss effects , its also a powerful hormone for metabolic health, brain function, gut healing, and heart protection

The current market for GLP-1s approved by the FDA for weight management includes Saxenda, Wegovy, Ozempic, Zepbound and Monjaro

Executive Council, European Dana Alliance for the Brain, European Research Council

The medication requires ongoing use to maintain weight loss, as demonstrated in the SURMOUNT-4 trial, where discontinuation led to weight regain

Semaglutide primarily acts as a GLP- 1 agonist, while Tirzepatide combines GLP- 1 and GIP mechanisms, enhancing its effectiveness for weight loss